FrancophonIA/ELRC3.0 huggingface dataset:
English: Therefore, the concomitant use of EXJADE with potent UGT inducers (e.g. rifampicin, carbamazepine, phenytoin, phenobarbital, ritonavir) may result in a decrease in EXJADE efficacy.
Slovenian: Zato lahko sočasna uporaba zdravila EXJADE z močnimi induktorji UGT (kot so rifampicin, karbamazepin, fenitoin, fenobarbital, ritonavir) zmanjša učinkovitost zdravila EXJADE.
English: • Guide for healthcare professionals
Slovenian: • Priročnik za zdravstvene delavce
English: Pharmacotherapeutic group: Iron chelating agents, ATC code: V03AC03
Slovenian: Farmakoterapevtska skupina: kelatorji železa, oznaka ATC: V03AC03
English: • Take EXJADE film-coated tablets either on an empty stomach or with a light meal.
Slovenian: • Filmsko obložene tablete EXJADE vzemite bodisi na prazen želodec ali z lahkim obrokom.
English: In severe cases this reintroduction could be conducted in combination with a short period of oral steroid administration.
Slovenian: V hudih primerih je mogoče ponovno uvesti zdravljenje v kombinaciji s kratkotrajno uporabo peroralnih steroidov.
English: EXJADE is not recommended for children aged under 2 years.
Slovenian: Uporaba zdravila EXJADE pri otrocih, mlajših od 2 leti, ni priporočljiva.
English: EXJADE may decrease the efficacy of hormonal contraceptives (see section 4.5).
Slovenian: Zdravilo EXJADE lahko zmanjša učinkovitost hormonskih kontraceptivov (glejte poglavje 4.5).
English: • A warning on the risk of overchelation and on the necessity of close monitoring of serum ferritin levels and renal and hepatic function.
Slovenian: • opozorilo glede tveganja za prekomerno kelacijo in potrebnosti skrbnega spremljanja vrednosti feritina v serumu ter ledvične in jetrne funkcije;
English: EXJADE is not recommended - if you are at an advanced stage of myelodysplastic syndrome (MDS; decreased production of blood cells by the bone marrow) or have advanced cancer.
Slovenian: Zdravilo EXJADE ni priporočeno - če imate napredovalo obliko mielodisplastičnega sindroma (MDS, zmanjšano nastajanje krvnih celic v kostnem mozgu) ali napredovalo obliko raka.
English: The safety profile was consistent with previous studies in adult MDS patients.
Slovenian: Varnostni profil je bil podoben kot v prejšnjih študijah odraslih bolnikov z mielodisplastičnim sindromom.
English: The principal analysis of the pivotal comparative study in 586 patients suffering from beta-thalassaemia and transfusional iron overload did not demonstrate non-inferiority of deferasirox dispersible tablets to deferoxamine in the analysis of the total patient population.
Slovenian: Osnovna analiza podatkov ključne primerjalne študije s 586 bolniki z beta talasemijo in s preobremenitvijo z železom zaradi transfuzij ni dokazala neinferiornosti deferasiroksa v obliki disperzibilnih tablet v primerjavi z deferoksaminom v analizi celotne populacije bolnikov.
English: How to take EXJADE:
Slovenian: Kako vzeti zdravilo EXJADE:
English: • Proteinuria (test should be performed prior to therapy and monthly thereafter)
Slovenian: • pri proteinuriji (preiskavo je treba izvesti pred začetkom zdravljenja, nato pa enkrat na mesec),
English: If such reactions occur, EXJADE should be discontinued and appropriate medical intervention instituted.
Slovenian: V primeru takih reakcij je treba zdravljenje z zdravilom EXJADE prekiniti in ustrezno strokovno ukrepati.
English: EXJADE has not been studied in patients with renal impairment and is contraindicated in patients with estimated creatinine clearance <60 ml/min (see sections 4.3 and 4.4).
Slovenian: Pri bolnikih z okvaro ledvic uporaba zdravila EXJADE ni proučena in je kontraindicirana pri bolnikih z oceno očistka kreatinina <60 ml/min (glejte poglavji 4.3 in 4.4).
English: How much EXJADE to take The dose of EXJADE is related to body weight for all patients.
Slovenian: Koliko zdravila EXJADE vzeti Odmerek zdravila EXJADE je pri vseh bolnikih odvisen od telesne mase.
English: Treatment with EXJADE will be overseen by a doctor who is experienced in the treatment of iron overload caused by blood transfusions.
Slovenian: Zdravljenje z zdravilom EXJADE bo nadzoroval zdravnik z izkušnjami z zdravljenem preobremenitve z železom zaradi krvnih transfuzij.
English: Lactose content The dispersible tablets contain lactose.
Slovenian: Vsebnost laktoze Disperzibilne tablete vsebujejo laktozo.
English: EXJADE can be used by people aged 65 years and over at the same dose as for other adults.
Slovenian: Ljudje, ki so stari 65 let ali več, lahko uporabljajo zdravilo EXJADE v enakih odmerkih kot odrasli sicer.
English: Deferasirox has been studied only in patients with baseline serum creatinine within the age-appropriate normal range.
Slovenian: Deferasiroks je bil proučen samo pri bolnikih z izhodiščno koncentracijo kreatinina v serumu v okviru starostno ustreznih normalnih vrednosti.
English: What EXJADE looks like and contents of the pack EXJADE granules are supplied as white to almost white granules in sachets.
Slovenian: Izgled zdravila EXJADE in vsebina pakiranja Zdravilo EXJADE zrnca je na voljo v obliki belih do skoraj belih zrnc v vrečicah.
English: EXJADE has minor influence on the ability to drive and use machines.
Slovenian: Zdravilo EXJADE ima blag vpliv na sposobnost vožnje in upravljanja strojev.
English: As a precaution, it is recommended that EXJADE is not used during pregnancy unless clearly necessary.
Slovenian: Iz varnostnih razlogov je priporočljivo, da se zdravila EXJADE med nosečnostjo ne uporablja, razen če je to nujno potrebno.
English: Adjustment steps (every 3-6 months)
Slovenian: >800 µg/l spremljanje enkrat na mesec koraki za prilagajanje (vsakih 3-6 mesecev)
English: Do not take a double dose on the next day to make up for the forgotten granules.
Slovenian: Naslednjega dne ne vzemite dvojnega odmerka, če ste pozabili vzeti prejšnji odmerek zrnc.
English: Continue taking EXJADE every day for as long as your doctor tells you.
Slovenian: Z vsakodnevnim jemanjem zdravila EXJADE nadaljujte tako dolgo, kot vam je naročil vaš zdravnik.
English: Do not stop taking EXJADE unless your doctor tells you to.
Slovenian: Ne prenehajte jemati zdravila EXJADE, če vam tega ne naroči zdravnik.
English: • That rises in serum transaminases may occur in patients treated with EXJADE o The need for liver function tests prior to prescription, then at monthly intervals or more often if clinically indicated o Not to prescribe to patients with pre-existing severe hepatic disease o The need to interrupt treatment if persistent and progressive increase in liver enzyme were noted.
Slovenian: • dejstvo, da pri bolnikih, ki se zdravijo z zdravilom EXJADE, lahko pride do zvišanja vrednosti serumskih transaminaz, o potrebnost izvajanja testov jetrne funkcije preden se predpiše zdravilo, nato pa v mesečnih intervalih ali bolj pogosto, če je klinično indicirano, o opozorilo, da se bolnikom s predhodno hudo boleznijo jeter zdravila ne sme predpisati, o potrebnost prekinitve zdravljenja, če pride do persistentnega in progresivnega zvišanja vrednosti jetrnih encimov;
English: The patient information pack should contain:
Slovenian: Komplet informacij za bolnike mora vsebovati:
English: Additional periodic distributions after launch should be performed, notably after substantial safety modifications of the product information justifying educational material updates.
Slovenian: Po prihodu zdravila na trg je občasno treba ponovno razdeliti izobraževalno gradivo, zlasti kadar ga je treba posodobiti zaradi pomembnih sprememb informacij o varnosti v informacijah o zdravilu.
English: • Take EXJADE once a day, every day, at about the same time each day.
Slovenian: • Vzemite zdravilo EXJADE enkrat na dan, vsakodnevno in sicer približno ob istem času.
English: The results of this study suggest that there is a positive impact of deferasirox on event-free survival (EFS, a composite endpoint including non-fatal cardiac or liver events) and serum ferritin levels.
Slovenian: Rezultati te študije kažejo, da deferasiroks pozitivno vpliva na preživetje brez dogodkov (event-free survival, EFS, sestavljen cilj opazovanja, ki ga določajo s srcem ali jetri povezani dogodki, ki niso smrtni) in na vrednosti feritina v serumu.
English: The Cmax was increased by 34% (90% CI: 27.9% - 40.3%); however a clinical exposure/response analysis revealed no evidence of clinically relevant effects of such an increase.
Slovenian: Cmax je sicer višja za 34 % (90-odstotni interval zaupanja: 27,9 % - 40,3 %), vendar rezultati analize klinične izpostavljenosti/odziva ne kažejo klinično pomembnih učinkov tega zvišanja.
English: If you forget to take EXJADE
Slovenian: Če ste pozabili vzeti zdravilo EXJADE
English: • That deferasirox causes rises in serum creatinine in some patients o The need to monitor serum creatinine
Slovenian: • dejstvo, da deferasiroks pri nekaterih bolnikih povzroča zvišanje koncentracije kreatinina v serumu o potrebnost spremljanja koncentracije kreatinina v serumu,
English: Doses (in mg/kg) must be calculated and rounded to the nearest whole sachet size.
Slovenian: Odmerke (v mg/kg) je treba izračunati in zaokrožiti na najbližjo vrednost jakosti vrečice.
English: It is recommended that serum ferritin be monitored every month and that the dose of EXJADE be adjusted, if necessary, every 3 to 6 months based on the trends in serum ferritin.
Slovenian: Priporočeno je spremljanje vrednosti feritina v serumu vsak mesec in prilagajanje odmerka zdravila EXJADE po potrebi vsakih 3 do 6 mesecev glede na trend vrednosti feritina v serumu.
English: Prior to launch of EXJADE in each Member State the Marketing Authorisation Holder (MAH) must agree about the content and format of the educational programme, including communication media, distribution modalities, and any other aspects of the programme, with the National Competent Authority.
Slovenian: Pred prihodom zdravila EXJADE na tržišče se mora imetnik dovoljenja za promet z zdravilom v vsaki državi članici s pristojnim nacionalnim organom dogovoriti o vsebini in obliki izobraževalnega programa ter o izbranih načinih komuniciranja ter posredovanja programa.
English: If you stop taking EXJADE
Slovenian: Če ste prenehali jemati zdravilo EXJADE
English: Weekly and Weekly
Slovenian: enkrat na teden in enkrat na teden
English: You may experience effects such as abdominal pain, diarrhoea, nausea and vomiting and kidney or liver problems that can be serious.
Slovenian: Morda bo prišlo do učinkov, kot so bolečine v trebuhu, driska, občutek slabosti in bruhanje, ter težav z ledvicami ali jetri, ki so lahko resne.
English: As a consequence, treatment with EXJADE is not recommended in these patients.
Slovenian: Iz tega razloga pri navedenih bolnikih zdravljenje z zdravilom EXJADE ni priporočeno.
English: 500-1,000 µg/l
Slovenian: 500-1.000 µg/l najvišji odmerek
English: The underlying conditions requiring transfusion included beta-thalassaemia, sickle cell disease and other congenital and acquired anaemias (myelodysplastic syndromes [MDS], Diamond-Blackfan syndrome, aplastic anaemia and other very rare anaemias).
Slovenian: Osnovne bolezni, zaradi katerih so bile potrebne transfuzije, so vključevale beta talasemijo, srpastocelično anemijo in druge prirojene in pridobljene anemije (mielodisplastični sindrom [MDS], Diamond-Blackfan sindrom, aplastično anemijo in druge zelo redke anemije).
English: As well as the requirements in the legislation, the following serious ADRs should be forwarded on an expedited basis to the appropriate competent authority as well as summarised in the above reports: o Increase in hepatic enzymes >10x ULN o Serious rise in creatinine o Results of renal biopsies, if available o Cataracts o Hearing loss o Gallstones
Slovenian: Kot zahteva zakonodaja, morajo biti sledeči resni neželeni učinki sporočeni po sistemu hitrega obveščanja ustreznemu pristojnemu organu in povzeti v zgoraj naštetih poročilih: o zvišanje vrednosti jetrnih encimov >10xZMN, o pomembno zvišanje koncentracije kreatinina, o izvidi ledvične biopsije, če so na voljo, o katarakte, o izguba sluha, o žolčni kamni.
English: EXJADE is not recommended in patients with severe hepatic impairment (Child-Pugh Class C).
Slovenian: Uporaba zdravila EXJADE ni priporočena pri bolnikih s hudo okvaro jeter (Child-Pugh stopnje C).
English: The MAH shall ensure that, at launch, in each Member State where EXJADE is marketed, all healthcare professionals and patients who are expected to prescribe, dispense and use EXJADE are provided with the following educational package for all available formulations (e.g. dispersible tablets, film-coated tablets and granules) for all indications:
Slovenian: Imetnik dovoljenja za promet z zdravilom mora zagotoviti, da bodo v vsaki državi članici, v kateri bo tržil zdravilo EXJADE, ob prihodu zdravila na tržišče vsi zdravstveni delavci in bolniki, ki bodo lahko predpisovali, razdeljevali ali uporabljali zdravilo EXJADE, prejeli enega od naslednjih kompletov izobraževalnega gradiva z informacijami za vse formulacije zdravila (npr. disperzibilne tablete, filmsko obložene tablete in zrnca) in za vse indikacije:
English: After a high-fat meal, only AUC was mildly increased (by 18%).
Slovenian: Po zaužitju obroka z visoko vsebnostjo maščob je bila nekoliko zvišana samo vrednost AUC za 18 %).
English: Caution should be exercised in patients who are taking EXJADE in combination with substances that have known ulcerogenic potential, such as NSAIDs, corticosteroids, or oral bisphosphonates, in patients receiving anticoagulants and in patients with platelet counts below 50,000/mm
Slovenian: Previdnost je potrebna pri bolnikih, ki jemljejo zdravilo EXJADE v kombinaciji z zdravilnimi učinkovinami, za katere je znano, da lahko povzročajo ulkuse, kot so nesteroidna protivnetna zdravila, kortikosteroidi ali peroralni difosfonati, pri bolnikih, ki prejemajo antikoagulante, in pri bolnikih s koncentracijo trombocitov, ki je nižja od 50.000/mm
English: o The need to interrupt treatment after a dose reduction if serum creatinine rises:
Slovenian: o potrebnost prekinitve zdravljenja po predhodnem zmanjšanju odmerka, če zvišana koncentracija kreatinina v serumu:
English: 252 dispersible tablets
Slovenian: 252 disperzibilnih tablet
English: How long to take EXJADE
Slovenian: Kako dolgo jemati zdravilo EXJADE
English: Interventional post-authorisation safety study (PASS): In order to assess the safety of deferasirox film-coated tablets in the paediatric population (especially when the tablets are crushed), the MAH shall conduct and submit the results of a safety study conducted according to an agreed protocol.
Slovenian: Neintervencijska varnostna študija po odobritvi zdravila (post-authorisation safety study, PASS): Za oceno varnosti uporabe deferasiroksa v obliki filmsko obloženih tablet pri pediatrični populaciji (zlasti glede drobljenja tablet) mora imetnik dovoljenja za promet z zdravilom po odobrenem protokolu izvesti varnostno študijo ter predložiti rezultate te študije.
English: Clinical efficacy and safety Clinical efficacy studies were conducted with deferasirox dispersible tablets.
Slovenian: Klinične študije za vrednotenje učinkovitosti so bile izvedene z deferasiroksom v obliki disperzibilnih tablet.
English: • Recommendations for treatment of non-transfusion-dependent thalassaemia (NTDT) syndromes: o Information that only one course of treatment is proposed for NTDT patients o A warning on the necessity of closer monitoring of liver iron concentration and serum ferritin in the paediatric population o A warning on the currently unknown safety consequences of long-term treatment in the paediatric population
Slovenian: • priporočila za zdravljenje sindromov talasemije, neodvisnih od transfuzij: o informacijo, da je predlagan le en cikel zdravljenja za bolnike, ki imajo katerega od sindromov talasemije, neodvisnih od transfuzij, o opozorilo glede potrebe o natančnejšem spremljanju koncentracije železa v jetrih in serumskega feritina pri pediatrični populaciji, o opozorilo glede zaenkrat še neznanih posledic kar se tiče varnosti pri dolgotrajnem zdravljenju pri pediatrični populaciji.
English: Treatment with EXJADE should be initiated and maintained by physicians experienced in the treatment of chronic iron overload.
Slovenian: Zdravljenje z zdravilom EXJADE naj uvede in nadaljuje zdravnik z izkušnjami pri zdravljenju kronične preobremenitve z železom.
English: Monitoring - First month after start of therapy or dose modification (including switch of formulation)
Slovenian: <60 ml/min spremljanje - prvi mesec po začetku zdravljenja ali spremembi odmerka (tudi po prehodu z ene formulacije na drugo)
English: • The need for a guidance table highlighting pre-treatment measurements of serum creatinine, creatinine clearance, proteinuria, hepatic enzymes, ferritin, such as:
Slovenian: • potrebnost vodenja in upoštevanja preglednice, ki opozarja na naslednje meritve pred zdravljenjem: koncentracije kreatinina v serumu, očistka kreatinina, proteinurije in vrednosti jetrnih encimov ter feritina, kot je prikazano:
English: Patient guide should contain the following key elements: o Information on the need for regular monitoring, and when it should be carried out, of serum creatinine, creatinine clearance, proteinuria, hepatic enzymes, ferritin o Information that renal biopsy may be considered if significant renal abnormalities occur o Availability of several oral formulations (e.g. dispersible tablets, film-coated tablets and granules) and the main differences associated with these formulations (i.e., different posology regimen, different conditions of administration notably with food)
Slovenian: Priročnik za bolnika mora vsebovati naslednje ključne vsebine: o podatke o potrebnosti rednega spremljanja in časovni razpored preiskav koncentracije kreatinina v serumu, očistka kreatinina, proteinurije, vrednosti jetrnih encimov in feritina, o obvestilo o možnosti, da je v primeru pojava pomembnih ledvičnih nepravilnosti treba razmisliti o ledvični biopsiji, o podatke o več peroralnih formulacijah zdravila (npr. disperzibilnih tabletah, filmsko obloženih tabletah in zrncih), ki so na voljo, in glavne razlike med temi formulacijami (to sta različen režim odmerjanja in različni pogoji jemanja, zlasti kar zadeva jemanje skupaj s hrano).
English: Serum creatinine, creatinine clearance (estimated with the Cockcroft-Gault or MDRD formula in adults and with the Schwartz formula in children) and/or plasma cystatin C levels should be monitored prior to therapy, weekly in the first month after initiation or modification of therapy with EXJADE (including switch of formulation), and monthly thereafter.
Slovenian: Koncentracijo kreatinina v serumu, očistek kreatinina (ocenjen po Cockcroft-Gaultovi ali MDRD formuli pri odraslih in po Schwartzovi formuli pri otrocih) in/ali vrednost cistatina C v serumu je treba najprej določiti pred začetkom zdravljenja, v prvem mesecu po uvedbi ali spremembi zdravljenja z zdravilom EXJADE (kar vključuje tudi prehod z uporabe ene formulacije zdravila na uporabo druge) jo je treba spremljati tedensko, kasneje pa enkrat mesečno.
English: • The maximum recommended daily dose for EXJADE dispersible tablets is 40 mg per kilogram body weight for patients receiving regular blood transfusions, 20 mg per kilogram body weight for adult patients not receiving regular blood transfusions and 10 mg per kilogram body weight for children and adolescents not receiving regular blood transfusions.
Slovenian: • Za bolnike, ki prejemajo redne transfuzije krvi, je največji priporočeni dnevni odmerek zdravila EXJADE v obliki disperzibilnih tablet 40 mg na kilogram telesne mase, za odrasle bolnike, ki ne prejemajo rednih transfuzij krvi 20 mg na kilogram telesne mase in za otroke in mladostnike, ki ne prejemajo rednih transfuzij krvi 10 mg na kilogram telesne mase.
English: Each pack contains 30 sachets.
Slovenian: Posamezno pakiranje vsebuje 30 vrečic.
English: When the granules were administered with apple sauce or yogurt, a food effect was absent.
Slovenian: Pri odmerjanju zrnc skupaj z jabolčno kašo ali jogurtom ni prišlo do vpliva hrane.
English: • Additional risk minimisation measures The MAH must inform the European Medicines Agency and the CHMP of the results of the surveillance programme in each Member State.
Slovenian: Imetnik dovoljenja za promet z zdravilom mora obvestiti Evropsko agencijo za zdravila in Odbor za zdravila za uporabo v humani medicini (CHMP) o rezultatih raziskovalnega programa v vsaki državi članici.
English: In patients with moderate hepatic impairment (Child-Pugh Class B), the dose should be considerably reduced followed by progressive increase up to a limit of 50% (see sections 4.4 and 5.2), and EXJADE must be used with caution in such patients.
Slovenian: Pri bolnikih z zmerno okvaro jeter (Child-Pugh stopnje B) je treba odmerek znatno znižati in nato postopno zviševati do meje 50 % (glejte poglavji 4.4 in 5.2).
English: Tests of genotoxicity in vitro were negative (Ames test, chromosomal aberration test) while deferasirox caused formation of micronuclei in vivo in the bone marrow, but not liver, of non-iron-loaded rats at lethal doses.
Slovenian: Testi genotoksičnosti in vitro so bili negativni (Amesov test, test kromosomskih aberacij) medtem ko je deferasiroks v smrtonosnih odmerkih in vivo povzročil tvorbo mikronukleusov v kostnem mozgu, ne pa v jetrih pri podganah, ki niso bile obremenjene z železom.
English: 28 dispersible tablets 84 dispersible tablets 252 dispersible tablets
Slovenian: 28 disperzibilnih tablet 84 disperzibilnih tablet 252 disperzibilnih tablet
English: Monthly monitoring of serum ferritin is recommended in order to assess the patient's response to therapy and to avoid overchelation (see section 4.2).
Slovenian: Priporočeno je mesečno spremljanje vrednosti feritina v serumu zaradi presoje bolnikovega odziva na zdravljenje in za preprečevanje prekomerne kelacije (glejte poglavje 4.2).
English: Although there was no significant effect (increase in the extent of absorption AUC by 18-19%; no change in Cmax) of a high-fat meal on deferasirox pharmacokinetics, it is recommended that deferasirox granules be taken either with or without a light meal (see section
Slovenian: Čeprav obrok z visoko vsebnostjo maščob ni bistveno vplival na farmakokinetiko deferasiroksa (prišlo je do povečanja AUC za 18-19 % zaradi povečanega obsega absorpcije, Cmax se ni spremenila), je priporočeno deferasiroks v obliki zrnc jemati bodisi skupaj z lahkim obrokom ali brez obroka (glejte poglavje 5.2).
English: Renal excretion of deferasirox and its metabolites is minimal (8% of the dose).
Slovenian: Izločanje deferasiroksa in njegovih presnovkov preko ledvic je le minimalno (8 % odmerka).
English: • Glycosuria in non-diabetics and low levels of serum potassium, phosphate, magnesium or urate, phosphaturia, aminoaciduria (monitor as needed).
Slovenian: • v primeru glikozurije pri tistih, ki nimajo sladkorne bolezni, in v primeru nizkih koncentracij kalija, fosfatov, magnezija ali uratov v serumu, fosfaturije in aminoacidurije (s spremljanjem po potrebi).
English: See leaflet for further information.
Slovenian: Za dodatne podatke glejte navodilo za uporabo.
English: What EXJADE looks like and contents of the pack
Slovenian: Izgled zdravila EXJADE in vsebina pakiranja
English: Each blister pack contains 30 or 90 film-coated tablets.
Slovenian: En pretisni omot vsebuje 30 ali 90 filmsko obloženih tablet.
English: Disperse tablets in water or fruit juice before swallowing.
Slovenian: Tablete pred zaužitjem raztopite v vodi ali sadnem soku.
English: Skin rashes may appear during EXJADE treatment.
Slovenian: Med zdravljenjem z zdravilom EXJADE se lahko pojavijo kožni izpuščaji.
English: Limited clinical data (29 patients with normal cardiac function at baseline) using MRI indicate that treatment with deferasirox 10-30 mg/kg/day (dispersible tablet formulation) for 1 year may also reduce levels of iron in the heart (on average, MRI T2* increased from 18.3 to 23.0 milliseconds).
Slovenian: Omejeni klinični podatki (29 bolnikov z normalnim delovanjem srca ob izhodišču), pridobljeni z magnetnoresonančnim slikanjem (MRI), kažejo, da zdravljenje z deferasiroksom v odmerku 10-30 mg/kg/dan (v obliki disperzibilnih tablet) v obdobju 1 leta lahko zniža tudi koncentracije železa v srcu (v povprečju se je MRI T2* podaljšal z 18,3 na 23,0 milisekunde).